Patents by Inventor Omid Veiseh

Omid Veiseh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200263196
    Abstract: Described herein are cell compositions comprising an active cell (e.g., an engineered active cell, e.g., an engineered RPE cell) or derivatives thereof, as well as compositions, pharmaceutical products, and implantable elements comprising an active cell, and methods of making and using the same. The cells and compositions may express a therapeutic agent useful for the treatment of a disease, disorder, or condition described herein.
    Type: Application
    Filed: September 27, 2018
    Publication date: August 20, 2020
    Inventors: Guillaume Carmona, Francisco Caballero Gonzalez, Richard Heidebrecht, Robert James Miller, Matthias Alexander Oberli, David Peritt, Jared A. Sewell, Devyn McKinley Smith, Omid Veiseh, Paul Kevin Wotton
  • Patent number: 10729818
    Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: August 4, 2020
    Assignees: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Arturo J. Vegas, Joshua C. Doloff, Omid Veiseh, Minglin Ma, Robert S. Langer, Daniel G. Anderson
  • Patent number: 10730983
    Abstract: Zwitterionic polymers or biocompatible polymers with improved properties for cell encapsulation, coating of devices, or a combination thereof are described. The biocompatible polymer contains a zwitterionic monomer, a monomer with a reactive side chain, and optionally another hydrophobic monomer or a neutral hydrophilic monomer. The zwitterionic polymers are cross-linked with a cross-linker via covalent bond to form a zwitterionic hydrogel in the presence of cells. Also provided, are methods of making and using the zwitterionic polymers.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: August 4, 2020
    Assignees: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Omid Veiseh, Volkan Yesilyurt, Arturo Vegas, Joshua Doloff, Daniel G. Anderson, Robert S. Langer
  • Patent number: 10709818
    Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: July 14, 2020
    Assignees: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Arturo J. Vegas, Joshua C. Doloff, Omid Veiseh, Minglin Ma, Robert S. Langer, Daniel G. Anderson
  • Patent number: 10683379
    Abstract: Described herein are polymers, polymeric gels, or a composition thereof, for drug delivery. The polymers, which include boronic-acid containing moieties (e.g., and polyol-containing moieties (e.g., are prepared by free-radical polymerization and can self-assemble into polymeric gels such as hydrogels. Also provided are methods or preparing the polymers, kits involving the polymers and/or polymeric gels or a composition thereof, for use as materials or delivery applications of an agent to a subject.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: June 16, 2020
    Assignee: Massachusetts Institute of Technology
    Inventors: Daniel Griffith Anderson, Eric Andrew Appel, Yizhou Dong, Robert S. Langer, Benjamin C. Tang, Omid Veiseh, Weiheng Wang, Matthew J. Webber, Kun Xue
  • Publication number: 20200039943
    Abstract: The present invention provides compounds, e.g., compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are implantable elements (e.g., devices and materials) comprising the same, as well as methods of use thereof, e.g., for treating or preventing a disease, disorder, or condition.
    Type: Application
    Filed: October 3, 2017
    Publication date: February 6, 2020
    Inventors: Omid Veiseh, Richard Heidebrecht, Paul Kevin Wotton, Matthias Alexander Oberli, Robert James Miller
  • Publication number: 20200016085
    Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.
    Type: Application
    Filed: September 26, 2019
    Publication date: January 16, 2020
    Inventors: Arturo J. Vegas, Joshua C. Doloff, Omid Veiseh, Minglin Ma, Robert S. Langer, Daniel G. Anderson
  • Publication number: 20200008718
    Abstract: CGMs containing a sensor electrode that is partially or completely coated with one or more layers of a material containing zwitterionic polymers are disclosed. With just a single calibration after implantation, CGMs containing the zwitterionic polymer coatings show reduced discordance between detected and actual blood glucose levels, during the crucial first one to three days, where current commercially available CGMs tend to show discordance with actual blood glucose levels.
    Type: Application
    Filed: June 13, 2017
    Publication date: January 9, 2020
    Applicants: Massachusetts Institute of Technology, The Children's Medical Center Corporation
    Inventors: Joshua DOLOFF, Xi XIE, Volkan YESILYURT, Omid VEISEH, Atieh SADRAEI, Daniel G. ANDERSON, Robert S. LANGER
  • Patent number: 10426735
    Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.
    Type: Grant
    Filed: August 3, 2015
    Date of Patent: October 1, 2019
    Assignees: Massachusetts Institute of Technology, The Children's Medical Center Corporation
    Inventors: Arturo J. Vegas, Joshua C. Doloff, Omid Veiseh, Minglin Ma, Robert S. Langer, Daniel G. Anderson
  • Publication number: 20190184067
    Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.
    Type: Application
    Filed: February 28, 2019
    Publication date: June 20, 2019
    Inventors: Arturo Vegas, Joshua C. Doloff, Omid Veiseh, Minglin Ma, Robert S. Langer, Daniel G. Anderson
  • Publication number: 20190134277
    Abstract: Neurological implants whose surfaces have been chemically and covalently modified to impart beneficial properties to the neurological implants are described. The neurological implants possess improved biocompatibility compared to a corresponding neurological implant that lacks the chemical modification. Following implantation in a subject, the surface-modified neurological implants induce a lower-foreign body response, compared to a corresponding unmodified product.
    Type: Application
    Filed: November 6, 2018
    Publication date: May 9, 2019
    Inventors: Omid Veiseh, Robert S. Langer, Daniel G. Anderson, William Shain, Brian W. Hanak, Samuel R. Browd, Robert F. Hevner
  • Publication number: 20190091139
    Abstract: Biomedical devices for implantation with decreased pericapsular fibrotic overgrowth are disclosed. The device includes biocompatible materials and has specific characteristics that allow the device to elicit less of a fibrotic reaction after implantation than the same device lacking one or more of these characteristic that are present on the device. Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.
    Type: Application
    Filed: November 26, 2018
    Publication date: March 28, 2019
    Inventors: Minglin Ma, Daniel G. Anderson, Robert S. Langer, Omid Veiseh, Joshua Charles Doloff, Delai Chen, Christian J. Kastrup, Arturo Jose Vegas
  • Publication number: 20190083495
    Abstract: Described herein are methods of preventing or reducing fibrosis comprising administering CSF1R inhibitors, coating formulations comprising CSF1R inhibitors, coatings comprising CSF1R inhibitors for implantable medical devices, CSF1R inhibitor coated implantable medical devices, as well as corresponding embodiments comprising additional agents.
    Type: Application
    Filed: April 4, 2017
    Publication date: March 21, 2019
    Applicant: Massachusetts Institute of Technology
    Inventors: Joshua C. Doloff, Shady Farah, Omid Veiseh, Arturo J. Vegas, Robert S. Langer, Daniel G. Anderson
  • Publication number: 20190046690
    Abstract: Products, such as devices, prostheses, and materials, whose surfaces have been modified in order to impart beneficial properties to these products are disclosed. The surface-modified products have improved biocompatibility compared to a corresponding product that lacks the modification. Following implantation in a subject, the surface-modified products induce a lower foreign-body response, compared to a corresponding unmodified product.
    Type: Application
    Filed: November 2, 2016
    Publication date: February 14, 2019
    Inventors: Arturo J. Vegas, Joshua C. Doloff, Omid Veiseh, Robert S. Langer, Daniel G. Anderson
  • Patent number: 10172791
    Abstract: Biomedical devices for implantation with decreased pericapsular fibrotic overgrowth are disclosed. The device includes biocompatible materials and has specific characteristics that allow the device to elicit less of a fibrotic reaction after implantation than the same device lacking one or more of these characteristic that are present on the device. Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: January 8, 2019
    Assignee: Massachusetts Institute of Technology
    Inventors: Minglin Ma, Daniel G. Anderson, Robert S. Langer, Omid Veiseh, Joshua Charles Doloff, Delai Chen, Christian J. Kastrup, Arturo Jose Vegas
  • Publication number: 20180360765
    Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.
    Type: Application
    Filed: August 22, 2018
    Publication date: December 20, 2018
    Inventors: Arturo J. Vegas, Joshua C. Doloff, Omid Veiseh, Minglin Ma, Robert S. Langer, Daniel G. Anderson
  • Publication number: 20180353643
    Abstract: Biomedical devices for implantation with decreased pericapsular fibrotic overgrowth are disclosed. The device includes biocompatible materials and has specific characteristics that allow the device to elicit less of a fibrotic reaction after implantation than the same device lacking one or more of these characteristic that are present on the device. Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.
    Type: Application
    Filed: May 17, 2016
    Publication date: December 13, 2018
    Inventors: Minglin Ma, Daniel G. Anderson, Robert S. Langer, Omid Veiseh, Arturo Jose Vegas, Joshua Charles Doloff, Delai Chen, Christian J. Kastrup
  • Publication number: 20180117216
    Abstract: Products, such as devices, prostheses, and materials, whose surfaces have been modified in order to impart beneficial properties to these products are disclosed. The surface-modified products have improved biocompatibility compared to a corresponding product that lacks the modification. Following implantation in a subject, the surface-modified products induce a lower foreign-body response, compared to a corresponding unmodified product.
    Type: Application
    Filed: November 2, 2016
    Publication date: May 3, 2018
    Inventors: Arturo J. Vegas, Joshua C. Doloff, Omid Veiseh, Robert S. Langer, Daniel G. Anderson
  • Publication number: 20170355799
    Abstract: Zwitterionic polymers or biocompatible polymers with improved properties for cell encapsulation, coating of devices, or a combination thereof are described. The biocompatible polymer contains a zwitterionic monomer, a monomer with a reactive side chain, and optionally another hydrophobic monomer or a neutral hydrophilic monomer. The zwitterionic polymers are cross-linked with a cross-linker via covalent bond to form a zwitterionic hydrogel in the presence of cells. Also provided, are methods of making and using the zwitterionic polymers.
    Type: Application
    Filed: June 13, 2017
    Publication date: December 14, 2017
    Inventors: Omid Veiseh, Volkan Yesilyurt, Arturo Vegas, Joshua Doloff, Daniel G. Anderson, Robert S. Langer
  • Patent number: 9784730
    Abstract: Nanoparticle having a crosslinked chitosan-polyethylene oxide oligomer copolymer coating to which O6-benzylguanine is covalently coupled, compositions that include the nanoparticle, and methods for using the nanoparticle to treat brain cancers.
    Type: Grant
    Filed: March 21, 2014
    Date of Patent: October 10, 2017
    Assignee: University of Washington through its Center for Commercialization
    Inventors: Miqin Zhang, Richard G. Ellenbogen, Forrest Kievit, John R. Silber, Zachary Stephen, Omid Veiseh